MSF Scientific Day is a unique opportunity to showcase medical and scientific research carried out in MSF programmes around the world. Presenting and debating the findings from our research is vital to improve the quality of our humanitarian programmes. There will be several topic s on tuberculosis.
To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.
World TB Day is celebrated on March 24 and there is a lot going on during this week and next to highlight the continued problem of TB in the world and the solutions to address the problem. Included is a list of publications, news items, events, and links related to TB and World TB Day 2013.
The FDA granted Janssen’s TB drug Bedaquiline accelerated approval for treatment of MDR-TB. A link is provided to the FDA press release and Janssen’s full press release is included.
A video from Medecins Sans Frontieres entitled “Multidrug-Resistance Tuberculosis: No Promises” on the situation of children affected with MDR-TB. It highlights the dire plight of children being treated for MDR-TB in Tajikistan.
Yesterday, Nov. 28th, the FDA Ant-infective Drug Advisory Committee voted to recommend Janssen’s Bedaquiline for accelerated approval for the treatment of MDR tuberculosis. A summary of the proceedings is included.
The week of November 12th was exciting with the 43rd Union World Conference, the WGND Annual Meeting (will be posting presentations soon), and the Stop TB Coordinating Board Meeting. Included are some news highlights and a listing of webcasts of interesting and presentations relevant for TB drug development and research.
The WHO released the Global Tuberculosis Report 2012 today. The main highlights and additional coverage are included.
This week, efficacy data from the recently completed Phase 2 randomized placebo-controlled trial in MDR patients evaluating delamanid with background treatment compared to placebo with background treatment was published yesterday in the New England Journal of Medicine. Delamanid (OPC-67683) is a new agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis. The abstract and overview of news coverage are presented, as well as, additional links to TB R&D news.